Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
5.38
-0.15 (-2.71%)
Mar 9, 2026, 3:31 PM EDT - Market open
Company Description
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Feb 8, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 334 |
| CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 United States | |
| Phone | 949 284 4555 |
| Website | evolus.com |
Stock Details
| Ticker Symbol | EOLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001570562 |
| CUSIP Number | 30052C107 |
| ISIN Number | US30052C1071 |
| Employer ID | 46-1385614 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Moatazedi | President, Chief Executive Officer and Director |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research and Development |
| Tatjana Mitchell | Chief Financial Officer |
| Nareg Sagherian | Head of Global Investor Relations and Corporate Communications |
| Jeffrey J. Plumer | General Counsel |
| Kurt Knab | Senior Vice President of Sales |
| Jessica Novak | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |